Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 MDMA-assisted psychotherapy for severe PTSD with fMRI sub-study
NL-OMON56347Phase 2Completed
- Sponsor
- MAPS Europe B.V.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by MAPS Europe B.V. Primary endpoint: Change in CAPS-5 Total Severity Score. Started Dec 2020; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON56347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56347.